Home > Ross Camidge: Brigatinib for Adult Patients With ALK+ Metastatic Non-small Cell Lung Cancer
Lung Cancer

Ross Camidge: Brigatinib for Adult Patients With ALK+ Metastatic Non-small Cell Lung Cancer

Published Online: June 9th 2020

touchONCOLOGY were delighted to speak to Ross Camidge, University of Colorado Cancer Center, to discuss the recent FDA approved of brigatinib for adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer.

Questions

1. What are the unmet needs in the treatment of patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer? (0:06)

2. What clinical data led to the approval of brigatinib in this treatment setting? (0:46)

3. What safety issues should be considered when prescribing brigatinib? (2:00)

4. In which patients is brigatinib likely to be particularly beneficial and in whom is it contraindicated? (3:56)

5. What are the options for patients who develop resistance to brigatinib? (5:00)

 

Speaker disclosure: Ross Camidge has received honoraria and research funding from Takeda.

Support: Interview and filming supported by Touch Medical Media. Commissioned in liaison with W2O Group.

Filmed in coverage of the 2020 ASCO Virtual Scientific Program.

Share this Video
Related Videos In Lung Cancer
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar